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We generated a high-growth H5N1/PR8 virus by plasmid-based reverse genetics. The virulence associated multiple basic amino acids of
the HA gene were removed, and the resulting virus is attenuated for chickens and chicken eggs. A formalin-inactivated oil-emulsion vaccine
was prepared from this virus. When SPF chickens were inoculated with 0.3 ml of the vaccine, the hemagglutinin-inhibition (HI) antibody
became detectable at 1 week post-vaccination (p.v.) and reached a peak of 10log2 at 6 weeks p.v. then slowly declined to 4log2 at 43 weeks
p.v. Challenge studies performed at 2, 3 and 43 weeks p.v. indicated that all of the chickens were completely protected from disease signs and
death. Ducks and geese were completely protected from highly pathogenic H5N1 virus challenge 3 weeks p.v. The duration of protective
immunity in ducks and geese was investigated by detecting the HI antibody of the field vaccinated birds, and the results indicated that 3 doses
of the vaccine inoculation in geese could induce a 34 weeks protection, while 2 doses induced more than 52 weeks protection in ducks. We
first reported that an oil-emulsion inactivated vaccine derived from a high-growth H5N1 vaccine induced approximately 10 months of
protective immunity in chickens and demonstrated that the oil-emulsion inactivated avian influenza vaccine is immunogenic for geese and
ducks. These results provide useful information for the application of vaccines to the control of H5N1 avian influenza in poultry, including
chickens and domestic waterfowl.
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An H5N1 avian influenza virus A/goose/Guangdong/1/
96 (GSGD/96) was first isolated from geese in Guangdong
province in China in 1996 (Chen et al., 2004; Xu et al.,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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China.1999). In 1997, H5N1 avian influenza virus caused disease
outbreaks in poultry in Hong Kong (Sims et al., 2003;
Shortridge et al., 1998), and a reassortant virus bearing the
hemagglutinin (HA) gene of the GSGD/96-like virus and the
NA gene and 6 internal genes from H6N1-subtype A/teal/
Hong Kong/W312/97-like virus (Chin et al., 2002) was
transmitted into humans and caused 6 deaths in 18 infected
people (Claas et al., 1998; Subbarao et al., 1998). In early
February of 2003, H5N1 virus reemerged in a family in
Hong Kong (Anonymous, 2003; Peiris et al., 2004). Starting
from late 2003, H5N1 influenza viruses began to spread and
caused disease outbreaks in China, Japan (Mase et al., 2005),
South Korea (Lee et al., 2005), Thailand, Vietnam, Indo-05) 153 – 162
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destruction of hundreds of millions of poultry, including
chickens, ducks and geese. In Thailand (Puthavathana et al.,
2005), Vietnam (Tran et al., 2004) and Cambodia, the viruses
were transmitted into humans and currently have caused
death in 50 of the 80 confirmed cases. H5N1 virus also
caused disease and death in tigers and leopards in Thailand
(Keawcharoen et al., 2004; Thanawongnuweeh, 2005).
These facts emphasize that the H5N1 viruses are not only
pathogens disastrous for domestic poultry but also bear a
substantial threat to public health.
Wild birds are regarded as natural reservoirs for avian
influenza viruses. Free-range domestic waterfowl have
chances to contact with both wild birds and domestic animals,
including poultry and mammals, such as pigs, and therefore
can function as intermediate hosts to transmit the avian
influenza viruses from wild birds to other hosts. H5N1 avian
influenza viruses have circulated in domestic waterfowl in
certain southeast Asia countries for a number of years (Chen
et al., 2004; Nguyen et al., 2005; Webster et al., 2002), and
these waterfowl usually do not show any disease signs, even
when they carry viruses that are highly pathogenic for
chickens (Alexander et al., 1986; Chen et al., 2004; Perkins
and Swayne, 2002; Webster et al., 2002). If active surveil-
lance is not rigorously carried out, these viruses will not be
detected unless they cause disease outbreaks or are trans-
mitted to sensitive hosts, such as chickens or turkeys. It is
quite common in southern China and other Asia countries that
pigs and ducks are housed in close proximity, especially in
farming villages, where families typically own a small
number of pigs and ducks. This proximity creates the
opportunity for viruses to transmit between ducks and pigs
and to adapt to mammalian hosts. Therefore, to prevent
waterfowl from H5N1 avian influenza infection would likely
cut the transmission chain of these viruses and greatly
enhance efforts to control and prevent disease outbreak in
other poultry and animals, including humans.
The culling of infected poultry is the time-honored
method to control or eradicate the highly pathogenic avian
influenza outbreaks and also the best-known way to prevent
transmission to humans. However, when the viruses are
widely spread over a huge area and involved in multiple
avian species, culling and physical containment are highly
unlikely to be successful. An alternative strategy would be
culling plus vaccination.
Egg-grown inactivated influenza vaccines have been
used for humans for many years and also for controlling
avian influenza in chickens and turkeys in some countries
(Abraham et al., 1988; Ellis et al., 2004; Karunakaran et al.,
1987; Capua et al., 2004), however, there is a lack of studies
on waterfowl vaccination. The ideal seed virus for vaccine
production is a strain of low pathogenicity that is well-
matched antigenically with the prevailing virus and capable
of growing well in eggs, which is crucial to mass production
(Kilbourne, 1969; Chen et al., 2003). All H5N1 viruses
isolated in China since 1996 have multiple basic aminoacids in the cleavage site of HA and therefore are all either
highly pathogenic or potentially highly pathogenic avian
influenza viruses unsuitable for vaccine production. The
main problems are the requirement for high-level bio-
containment facilities to adequately handle these viruses and
the inability to obtain high yields of virus in embryonated
chickens’ eggs (Richmond and McKinney, 1993; Subbarao
and Katz, 2004; Takada et al., 1999; Zambon, 1998).
Plasmid-based reverse genetics, developed in the late
1990s (Fodor et al., 1999; Garcia-Sastre and Palese, 1993;
Hoffmann et al., 2000a,b; Neumann et al., 1999), is a
powerful tool to generate ideal reassortant influenza vaccine
candidates (Hoffmann et al., 2002; Lipatov et al., 2005;
Marsh and Tannock, 2005; Nicolson et al., 2005; Schickli et
al., 2001; Webby et al., 2004). Previous studies indicated
that the A/goose/Guangdong/1/96 (GSGD/96) virus is the
HA gene donor of the avian influenza viruses circulating in
the poultry in China (Chen et al., 2004), and the HA gene of
GSGD/96 virus has been proved to be very immunogenic in
the recombinant fowlpox vaccine and DNA vaccine studies
(Qiao et al., 2003; Chen et al., 2001). In this study, we
generated a low pathogenicity H5N1 reassortant virus that
derives its HA and NA genes from GSGD/96 virus and 6
internal genes from the high-growth A/Puerto Rico/8/34
(PR8) virus by plasmid-based reverse genetics, as described
previously (Subbarao et al., 2003). The biological properties
of the virus were characterized, and the efficacy of a
formalin-inactivated vaccine derived from the virus was
evaluated. Antibody detection and challenge studies indi-
cated that one dose of the vaccine preparations was able to
induce 10 months of protective immune response in SPF
chickens under the experimental conditions. We also
demonstrated that this inactivated vaccine is immunogenic
in ducks and geese and is able to completely protect these
waterfowl from highly pathogenic H5N1 virus challenge.Results
Generation of a reassortant H5N1/PR8 virus
GSGD/96 is the first H5N1 AIV isolated in China in
1996, and phylogenetic data suggested that the GSGD/96-
like virus is the HA gene donor of the Hong Kong 97 H5N1
human influenza viruses. Avian influenza surveillance has
been conducted in China since 1996, and a series of H5N1
AIV strains have been isolated from health ducks during the
last several years. However, the antigenicity of these isolates
was similar to the GSGD/96 (the heterologous HI titers were
within a 2-fold range when compared with the homologous
titers of these viruses) (Chen et al., 2004). Therefore, we
selected the GSGD/96 as the HA and NA donor to generate
the reassortant virus. The multiple basic amino acids of the
HA cleavage site (RERRRKKR,GLF) that are associated
with the virulence of the H5 avian influenza virus in
chickens and mammals were changed into RETR,GLF, a
Fig. 1. Growth properties of H5N1 viruses in embryonated eggs. 0.1 ml of
100EID50 of the Re-1 reassortant virus (>) or wild-type GSGD/96 virus (o)
were inoculated into the allantoic cavities of 10-day-old embryonated eggs,
and the allantoic fluid of five eggs in each group was harvested at the time
points of 24, 36, 48, 60 and 72 h post-inoculation and pooled for checking
the HA titers.
Fig. 2. HI antibody duration induced by inactivated vaccine derived from
Re-1 strain in SPF chickens. Three-week-old white Leghorn SPF chickens
were injected intramuscularly (i.m.) with 0.3 ml of formalin-inactivated
vaccine, and sera were collected randomly from 8 chickens on a weekly
base for HI antibody detection. The bars indicate the standard deviation.
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(Hatta et al., 2001; Perdue et al., 1997; Senne et al., 1996).
A PR8-based reassortant virus, A/Harbin/Re-1/2003 (Re-1),
which contains the HA and NA genes of GSGD/96, was
generated by plasmid-based reverse genetics, and the
genotype was confirmed by sequencing the full length of
the HA and NA genes and part of each internal gene
fragment. Antigenic analysis revealed that Re-1 bears the
same antigenicity as GSGD/96. Plaque assay performed in
MDCK cells indicated that Re-1 lost the ability to form
plaque in the absence of TPCK trypsin, which is consistent
with the results of previous reports (Liu et al., 2003a;
Subbarao et al., 2003).
In vitro growth properties
Chicken eggs produced whole virus inactivated vaccines
were used for prevention of influenza in humans, poultry
and other animals. The high growth property of the vaccine
strain is very important for mass production of the vaccine.
Ten-day-old embryonated chicken eggs were inoculated
with 100 EID50 of Re-1 or GSGD/96 virus, the viruses were
harvested at different time points, and the HA titers were
checked (Fig. 1). The wild-type GSGD/96 killed all of the
eggs within 24–48 h, and the titers stopped increasing after
that. However, the reassortant virus Re-1 did not kill eggs
even 72 h after inoculation, and the HA titers reached
11log2 (Fig. 1).
Pathotyping and replication in chickens
Chickens inoculated with the Re-1 virus did not exhibit
disease signs or death during the observation period. A very
low titer of virus shedding (from undiluted samples) was
detected from 3 of 10 chickens in the oropharyngeal swabs
on day 3 post-inoculation, and 7 of 10 chickens had
seroconverted by day 14 p.i. All chickens in the GSGD/96
inoculated group died during the observation period, and
the average titers of the shedding viruses were 2.5–4.5log10EID50 from the oropharynx and 2.8–3.5 log10EID50
from the cloacae.
Immunogenicity and protective efficacy of Re-1
formalin-inactivated vaccine in chickens
0.3 ml of formalin-inactivated vaccines (containing 2.8
Ag of the HA protein) prepared from the Re-1 virus were
i.m. injected into 3-week-old SPF chickens, and sera was
collected on a weekly base to check the dynamic changes in
the HI antibody titer. As shown in Fig. 2, the HI antibody
was detected at 1-week post-vaccination (p.v.) and reached
the peak of 10log2 at 6 weeks p.v. then very slowly declined
to 4log2 at 43 weeks p.v. (Fig. 2).
Our unpublished data indicated that, when the HI
antibody titers of chickens increased to 4log2 or higher at
2 or 3 weeks after vaccination, the chickens were completely
protected from virus challenge. To determine whether the
long-lasting HI antibody of the immunized chickens still
correlated with protection, groups of chickens were chal-
lenged with the homologous highly pathogenic virus GSGD/
96 at the different time points of 2, 3 and 43 weeks p.v.,
respectively. The results shown in Table 1 indicate that the
vaccinated chickens were completely protected from the
highly pathogenic homologous virus GSGD/96 challenge at
2, 3 and 43 weeks p.v., although very low titers of virus (from
undiluted samples) were recovered from the oropharyngeal
swabs of one chicken at day 3 when challenged at 2 weeks
p.v. (Table 1). Chickens in the control groups shed virus from
both oropharynx and cloaca and died prior to day 6 after
challenge (Table 1). These results demonstrate that, after one
dose inoculation, chickens were protected from highly
pathogenic virus challenge for at least 43 weeks (10 months).
To evaluate the protective efficacy of the Re-1 vaccine
against the H5N1 avian influenza viruses isolated in 2004,
we challenged the chickens at 3 weeks p.v. with A/chicken/
Tianjing/65/2004 (H5N1) (CKTJ/04) and A/duck/Shanghai/
16/2004 (H5N1) (DKSH/04), respectively. The results in
Table 1 show that the chickens were completely protected
from death and disease, although lower titers of virus
Table 1
Protective efficacy of the H5N1 formalin-inactivated vaccines in SPF chickens
Administrationa Virus isolation from the swabs on different days p.c.: shedding/total (log10EID50) Survival/total
Vaccines Challenge
virus
Challenge time
(weeks p.v.)
Day 3 Day 5 Day 7
Oropharyngeal Cloacal Oropharyngeal Cloacal Oropharyngeal Cloacal
Experiment I
Re-1 GSGD/96 2 1/8 (0.9) 0/8 0/8 0/8 0/8 0/8 8/8
Control GSGD/96 2 8/8 (3.1 T 0.6) 8/8 (2.4 T 1.2) 5/5 (2.4 T 0.6) 5/5 (2.9 T 0.5) /b /b 0/8
Re-1 GSGD/96 3 0/8 0/8 0/8 0/8 0/8 0/8 8/8
Control GSGD/96 3 8/8 (3.3 T 0.9) 8/8 (2.2 T 1.3) 6/6 (2.4 T 0.7) 6/6 (2.7 T 0.6) /b /b 0/8
Re-1 GSGD/96 43 0/8 0/8 0/8 0/8 0/8 0/8 8/8
Control GSGD/96 43 8/8 (3.1 T 0.6) 8/8 (2.6 T 0.6) 1/1 (1.9) 1/1 (1.4) /b /b 0/8
Experiment II
Re-1 CKTJ/04 3 2/8 (1.0 T 0.9) 0/8 0/8 0/8 0/8 0/8 8/8
Control CKTJ/04 3 8/8 (4.1 T 0.5) 8/8 (3.8 T 0.8) /b /b /b /b 0/8
Re-1 DKNH/04 3 0/8 0/8 0/8 0/8 0/8 0/8 8/8
Control DKNH/04 3 8/8 (3.9 T 0.7) 8/8 (4.3 T 0.3) /b /b /b /b 0/8
a Groups of 3-week-old SPF chickens were vaccinated with 0.3 ml of the vaccine preparations and challenged with GSGD/96 at different time points of 2, 3,
26 and 43 weeks post-vaccination, respectively, in experiment I. In experiment II, groups of vaccinated chickens were challenged with two H5N1 avian
influenza viruses isolated in China in 2004 at 3 weeks p.v.
b Chickens died.
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the 8 chickens challenged with CKTJ/04 virus. All chickens
in the control groups shed high titers of virus through both
oropharynx and cloaca and died within 2 days post-
challenge (Table 1).
The vaccine efficacy in geese
Laboratory studies
Three-week-old geese were immunized with 0.5 ml of
the vaccine preparation, and only 2 of 5 geese survived from
challenge with highly pathogenic virus at 2 weeks afterTable 2
Vaccine efficacy of the H5N1-inactivated vaccine in geese and ducks
Administrationa Virus isolation from the swabs collected o
positive/total (titers, log10EID50)
Animals Group and
vaccination
schedule
Challenge
time
(weeks p.v.)
Day 3 Day
Oropharyngeal Cloacal Orop
Geesea Vaccinated 2 1/5 (0.9) 0/5 (<) 4/5 (
Control 2 3/5 (1.6 T 01.3) 0/5 (<) 5/5 (
Vaccinated 3 0/5 (<)c 0/5 (<) 0/5 (
Control 3 0/5 (<) 1/5 (1.5) 5/5 (
Field
geese
Vaccinated 34d 0/10 0/10 0/10
Control /e 9/10 (1.4 T 1.1) 4/10 (0.9 T 0.7) 9/9 (
Ducksa Vaccinated 3 0/30 (<) 0/30 (<) 0/30
Control 3 13/15 (2.1 T 0.8) 8/15 (1.8 T 0.6) 7/15
Field
ducks
Vaccinated 51f 2/10 (0.6 T 0.1) 0/10 (<) 0/10
Control /g 10/10 (3.0 T 0.6) 3/10 (1.2 T 1.1) 5/9 (
a 3-week-old avian influenza serological negative geese or ducks were vaccinat
107.5EID50 of the highly pathogenic virus DKSH/04 in 0.1 ml volume intranasal
b All geese in that group died.
c ‘‘<’’ means virus was not detected from undiluted samples.
d Geese were challenged at 34 weeks after the first shot (20 weeks after the thi
e Eight-month-old avian influenza negative geese were used as control.
f Ducks were challenged 52 weeks after the first shot (38 weeks after the seco
g Ten-month-old avian influenza negative ducks were used as control.immunization, with virus shedding from both oropharynx
and cloaca detected on days 3, 5 and 7 after challenge.
However, the geese were completely protected from
challenge at 3 weeks after vaccination, none of the geese
shed virus, no disease signs were observed, and no geese
died. All geese in the control group died within 7 days after
challenge, and virus shedding was detected on days 3, 5 and
7 (Table 2).
Field studies
The HI antibody duration in the geese vaccinated in the
field is shown in Fig. 3a. During the 36 weeks investigationn different days after challenge: Survival/
total
5 Day 7
haryngeal Cloacal Oropharyngeal Cloacal
2.0 T 1.4) 3/5 (0.8 T 0.4) 1/3 (2.0) 2/3 (2.1 T 1.4) 3/5
2.4 T 0.1) 3/5 (1.8 T 1.0) /b /b 0/5
<) 0/5 (<) 0/5 (<) 0/5 (<) 5/5
1.7 T 0.4) 3/5 (1.1 T 0.5) 2/2 (2.4 T 0.2) 2/2 (1.7 T 0.3) 0/5
0/10 0/10 0/10 10/10
3.2 T 0.7) 3/9 (0.9 T 0.7) 1/1 (3.3) /b 0/10
(<) 0/30 (<) 0/30 (<) 0/30 (<) 30/30
(2.1 T 1.0) 5/15 (0.8 T 0.3) 0/2 (<) 0/2 (<) 2/15
(<) 0/10 (<) 0/10 (<) 0/10 (<) 10/10
1.8 T 1.2) 1/9 (0.7 T 0.5) 0/9 (<) 0/9 (<) 9/10
ed with 0.5 ml of the Re-1 vaccine preparations and were challenged with
ly at 2 or 3 weeks p.v.
rd shot).
nd shot).
Fig. 3. HI antibody duration induced by inactivated vaccine derived from
the Re-1 strain in geese (a) and ducks (b). Field geese were vaccinated 2
more times with 1.5 ml of the vaccine preparation with 13.8 Ag HA protein
at 4 and 17 weeks, respectively, after the first shot with 0.5 ml of the
vaccine preparation containing 4.6 Ag HA protein. Ducks received the
second shot of 1.0 ml of the vaccine preparation with 9.2 Ag HA protein at
14 weeks after the first shot with 0.5 ml of the vaccine preparation
containing 4.6 Ag HA protein. Sera were collected randomly from 20 of
each type of birds on a weekly base for the HI antibody detection. The bars
indicate the standard deviation, and the arrows indicate the time points for
the second or third shots.
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developed HI antibody very slowly after the first shot with
0.5 ml of the vaccine containing 4.6 Ag HA protein, and the
titers reached 3log2 by 3 weeks p.v and increased slightly at
4 weeks p.v. However, the antibody increased sharply and
reached the peak of 10log2 at 3 weeks after the second
immunization with a high dosage of 1.5 ml vaccine
containing 13.8 Ag HA protein and then gradually declined
to 4log2 by 13 weeks (17 weeks after the first immuniza-
tion). The pattern of the antibody titers after the third shot is
similar to that induced by the second shot, but the antibody
duration was 4 weeks longer than the previous one. Virus
was not detected from any swabs that were randomly
collected from 20 geese every 2 weeks.
When the HI antibody declined to 4log2 (17 weeks after
the third shot), 10 geese were transferred to negative
pressure isolates in the laboratory and challenged with
107.5EID50 of highly pathogenic H5N1 avian influenza virus
DKSH/2004. As shown in Table 2, all of the vaccinated
geese were completely protected from the virus challenge,
no virus shedding, no clinical disease signs, and no deaths
were observed, while all of the unvaccinated control geeseshed viruses from both oropharynx and cloacae and died
within 9 days after challenge (Table 2).
Vaccine efficacy in ducks
Laboratory studies
Three-week-old avian influenza serological negative
ducks were immunized with 0.5 ml of the Re-1 vaccine
preparations and were challenged 3 weeks after immuniza-
tion with highly pathogenic avian influenza virus. As shown
in Table 2, all the vaccinated ducks were completely
protected and stayed healthy, and virus shedding was not
detected from any ducks during the 1-month observation
period. However, all of the control ducks shed different
titers of virus at day 3 or 5 post-challenge, and 13 of 15
ducks died before day 6 (Table 2).
Field studies
To investigate the antibody kinetics induced by vacci-
nation in ducks, antisera were collected randomly from 20
of the vaccinated ducks in the field on a weekly base for
HI antibody detection. As shown in Fig. 3b, ducks
developed HI antibody very quickly compared with geese.
The average HI antibody titer of 3log2 was detected 1
week p.v., reached the peak of 8log2 at 4 weeks p.v and
then gradually declined to 4log2 by 14 weeks p.v. The
antibody titers increased rapidly to 10log2 1 week after the
second shot and remained at 6log2 38 weeks later (52
weeks after first dose, the end of the observation period)
(Fig. 3b). Virus was not detected from any swabs that were
randomly collected from the ducks.
At 38 weeks after the second shot, 10 ducks from the
field were transferred to the laboratory and challenged with
107.5EID50 of the H5N1 highly pathogenic virus DKSH/04
i.n., all of the vaccinated ducks were protected from
clinical disease and death, though low titers of virus (from
undiluted samples) were detected from the oropharyngeal
swabs of 2 ducks on day 3 p.c. All of the ducks in the
control group shed viruses through the oropharynx, and 3
shed viruses through cloacae on day 3 p.c. Virus was also
detected from the oropharyngeal swabs of 5 ducks and
cloacal swabs of 3 ducks on day 5, while no virus was
detected from any ducks on day 7 p.c. (Table 2). Only one
duck in the control group died during the 2-week
observation period, indicating that adult ducks are much
more resistant to the H5N1 avian influenza viruses
compared with the young ducks.Discussion
Inactivated whole virus vaccines have been used in
several countries in an effort to control the outbreaks caused
by highly pathogenic H5 and H7 viruses (Capua et al., 2003;
Ellis et al., 2004). Using plasmid-based reverse genetics, we
have generated the low-pathogenicity/high-growth H5N1
G. Tian et al. / Virology 341 (2005) 153–162158virus Re-1 strain, which is antigenically well-matched with
the H5N1 highly pathogenic viruses found in China. The
animal studies indicate that the H5N1 vaccine derived from
the Re-1 strain is immunogenic and efficient in chickens,
ducks and geese.
Numerous studies have confirmed the efficacy of the oil-
emulsion inactivated vaccine for avian influenza in chickens
and turkeys (Abraham et al., 1988; Capua et al., 2003, 2004;
Ellis et al., 2004; Lee et al., 2004; Liu et al., 2003a; Stone,
1987; Swayne et al., 2001), and most of the efficacy
evaluations have been based on a challenge study performed
a few weeks after vaccination, when the HI antibody titers
reach or are around their peak. Our previous studies had
indicated that the vaccinated chickens could be completely
protected from highly pathogenic avian influenza virus
challenge when the HI antibody titers to the challenge virus
equaled or were greater than 4log2, a titer that can be easily
induced by inactivated vaccine immunization. Therefore, a
challenge study conducted 3 or 4 weeks after vaccination
actually may not reflect how well a vaccine will work or
how long the protective immunity will last in vaccinated
birds in the field. The challenge study and HI antibody
detection performed in the present study demonstrated that
the protective immunity in SPF chickens induced by the Re-
1 inactivated vaccine last for 10 months, which is 4 months
longer than the duration induced by the H5N2 vaccine (from
a strain of A/turkey/England/N-28/73) currently used in
China (data not shown). HA protein in the Re-1 and H5N2
vaccines are 2.8 Ag and 1.9 Ag per dose (0.3 ml),
respectively, and the higher HA protein content may be
correlated with the longer protection in the vaccinated
chickens.
An ideal vaccine candidate would induce cross protec-
tion against viruses from different antigenic groups within
the subtype. As we have reported, there is no evidence of
significant antigenic drift of the H5N1 viruses isolated
from 1996–2002 in China (Chen et al., 2004). However,
certain viruses isolated in 2004 are quite different from the
GSGD/96 virus. The HA gene homologies of DKSH/04
and CKTJ/04 with GSGD/96 virus are 94.6% and 94.3%,
respectively, and the HI titers of DKSH/04 and CKTJ/04
to the antisera of GSGD/96 are 4- and 8-fold lower,
respectively, than the homologous titers (data not shown).
The present studies show that immunization with the Re-1
vaccine could induce complete protection against homol-
ogous GSGD/96 challenge and against the heterologous
virus DKSH/04 as well.
Free-range domestic waterfowl have the opportunity to
contact with wild birds and also domestic poultry and
animals. Therefore, they play an important role in trans-
mission of virus from wild birds to other domestic poultry
and other animals, including humans. China is heavily
populated with free-range domestic waterfowl, and the
H5N1 virus has circulated in healthy ducks in Southern
China for several years (Chen et al., 2004; Guan et al., 2002;
Webster et al., 2002). The present study and Sturm-Ramirez’s recent report (Sturm-Ramirez et al., 2004)
indicate that certain recently isolated H5N1 viruses are
lethal for ducks. Therefore, vaccination of domestic water-
fowl to prevent H5N1 virus infection is crucial for effective
disease control and eradication in animals and for public
health as well. In the present study, we demonstrate that an
oil-emulsion inactivated vaccine derived from the Re-1
strain is immunogenic in ducks and geese. One dose of 0.5
ml of the vaccine immunized ducks or geese was completely
protected from highly pathogenic H5N1 virus challenge, but
the duration of protective immunity was different. Two
shots of the vaccine in ducks induced more than 52 weeks
protection. The reaction of geese to the vaccine is quite
different from ducks and chickens. The antibody titers rose
slowly after the first shot, and the duration was relatively
short even after the second and third shots, compared with
the duration in ducks and chickens, suggesting that the
vaccination program for different avian species should be
carefully planned for field applications.
Avian influenza vaccine induced protection was both
dose- and vaccine strain-dependent. Swayne et al. reported
that the H5 avian influenza viruses have been shown to
replicate in vaccinated but clinically normal chickens, and
transmission of AIV might potentially occur within
vaccinated flocks (Swayne et al., 2001). However, Ellis
et al. reported that H5 vaccine can interrupt virus trans-
mission in chickens in a field setting (Ellis et al., 2004). In
the present study, the field tests were conducted in the
free-range geese and ducks on a farm where a highly
pathogenic H5N1 avian influenza outbreak had taken place
in the beginning of 2004. The negative results of the virus
isolation from the swabs of the vaccinated birds indicate
that they were free from H5 avian influenza viruses
infection. The negative isolation results of the swabs from
the challenged vaccinated birds indicate that the present
Re-1 vaccine could prevent chickens, ducks and geese
from both affliction with H5N1 virus infection and
efficient shedding of virus.
It is reported that the use of an inactivated influenza
vaccine containing the marker NA permits differentiating
infected from vaccinated animals (DIVA) (Capua et al.,
2003; Lee et al., 2004; Liu et al., 2003a). A previous report
(Liu et al., 2003b) and our avian influenza strain surveil-
lance data have revealed that multiple HA and NA subtypes
of avian influenza viruses exist in the domestic poultry in
China, therefore, using NA as a marker to differentiate the
infected from the vaccinated birds may not be applicable.
Qiao et al. (2003) reported that a recombinant fowlpox virus
containing the HA and NA genes from H5N1 viruses was
able to provide protection against lethal H7N1 viruses
challenge, indicating that the NA protein also has an
important role in the vaccine efficacy. Therefore, in the
present study, we chose to use both the HA and NA genes of
the H5N1 virus to generate vaccine strain to match and
provide a better protection to the prevalent H5N1 viruses.
Applications of unvaccinated sentinel birds should be a
G. Tian et al. / Virology 341 (2005) 153–162 159highly recommended option for detection of virus that may
introduce into the vaccinated flocks.
In summary, we generated a high-growth H5N1 reassor-
tant as an inactivated vaccine seed virus by plasmid-based
reverse genetics and demonstrated that one dose of
inactivated oil-emulsion vaccine could induce 10 months
of protective immune response in chickens. Moreover, we
first provided evidence that the oil-emulsion inactivated
vaccine is indeed immunogenic and then proved the efficacy
in domestic ducks and geese, which demonstrates that it is
actually feasible to apply vaccines to protecting domestic
waterfowl from H5N1 influenza virus infection. It is worthy
to note that complete control and eradication of H5N1
highly pathogenic avian influenza viruses only be ultimately
achieved by a combination of vaccination, improved
biosecurity, extensive surveillance and an effective monitor-
ing program. An effective vaccine is one crucial player in
this multi-part scenario.Materials and methods
Viruses and cells
GSGD/96 was the first H5N1 HPAIV isolated in China
and has been characterized as previously reported (Chen et
al., 2004; Xu et al., 1999). CKTJ/04 and DKSH/04 were
isolated during the 2004 outbreaks. The viruses were
propagated in the allantoic cavity of 10-day-old SPF
chicken embryonated eggs and kept in a 70 -C freezer
before use for RNA extraction and challenge study. Plaque
assay was performed in MDCK cells and with or without the
addition of 0.5 Ag of TPCK trypsin (Klenk et al., 1975).
Virus rescue was carried out in Vero cells maintained in
DMEM with 10% of FBS (Invitrogen Corp., Carlsbad, CA,
USA), HEPERS (Invitrogen Corp., Carlsbad, CA, USA)
and penicillin/streptomycin.
Plasmids
Twelve plasmids including the 8 vRNA of all the genome
fragments and 4 mRNA expression plasmids of PB2, PB1,
PA and NP of the PR8 virus were kindly provided by Drs.
Brownlee and Fodor from Oxford University. The con-
struction of these plasmids has been described in a previous
report (Subbarao et al., 2003). An mRNA and vRNA bi-
directional transcription plasmid pBD was constructed by
inserting the PolI promoter and Ribozyme sequence frag-
ment of the plasmid pPolI-SapI-Rib (a gift from Dr. Peter
Palese, Mount Sinai School of Medicine, New York) into the
XbaI site of pCI (Promega) in the sequence of the CMV-Rib-
PolI-SV40 poly A signal. The full-length HA gene and NA
gene of GSGD/96 were amplified by RT-PCR and inserted
into the SapI site of pBD. The amino acid sequence of the
cleavage site of the HA RERRRKKR,GLF was changed
into RETRF,GLF by PCR as described by Li et al. (1999).Virus rescue
A monolayer of Vero cells in a 6-well plate was
prepared, and transfection was conducted within 24 h of
the cells being planted. 0.4 Ag of each plasmid (HA and
NA bi-directional plasmids, the remaining 6 gene tran-
scription plasmids from PR8 and 4 protein expression
plasmids from PR8) were added into 250 Al Opti-MEM
(Invitrogen Corp., Carlsbad, CA, USA) and were mixed by
vortex. Twelve microliter of the transfection reagent
Lipofectamine 2000 (Invitrogen Corp., Carlsbad, CA,
USA) was added into 250 Al Opti-MEM and mixed well
gently. Five minutes later, the diluted reagent was mixed
with the plasmid, and the mixture was kept at room
temperature for 20–30 min. The cells were washed twice
with 2 ml Opti-MEM, and then the DNA–transfection
reagent mixtures were added directly to the cells. After 16-
h incubation at 37 -C in the CO2 incubator, the medium
was replaced with 2 ml fresh Opti-MEM with the addition
of 0.5 Ag of TPCK trypsin and was kept for two more
days at 37 -C. Then, the supernatant was inoculated into
the allantoic cavity of 10-day-old embryonated SPF eggs.
After 48-h incubation at 35 -C, the allantoic fluid was
harvested, and the virus was identified by hemagglutina-
tion assay using 0.5% chickens red blood cells.
Growth property analysis
10-day-old SPF embryonated eggs were inoculated with
100EID50 of different viruses, and 10 eggs from each group
were harvested and pooled at 24, 36, 48, 60 and 72 h,
respectively, after inoculation. The HA titers were checked
by using 0.5% chicken red blood cells.
Pathogenicity studies in chickens
Ten 4-week-old White Leghorn SPF chickens housed in
isolator cages were inoculated with wt GSGD/96 and Re-1
transfectant viruses at a standard dose (0.2 ml of a 1:10
dilution of stock virus) by the intravenous (i.v.) route and
were kept for 14 days for observation of disease signs and
death. Oropharyneal and cloacal swabs were collected for
virus isolation on day 3 post-infection (p.i). On day 14 p.i.,
all surviving chickens were euthanized, and sera were
collected and tested for evidence of seroconversion by agar
gel precipitin (AGP) test using a baculovirus expressed
nucleoprotein of influenza A virus as antigen and HI tests.
Preparation of formalin-inactivated vaccines
Virus was inoculated into the allantoic cavities of 10-
day-old embryonated eggs and was harvested after 72-h
incubation at 35 -C. To detect the content of the HA
protein, we run the SDS-PAGE of the freshly harvested
allantoic fluid and scanned the gel using the GeneSnap
software of Bio Imaging Systems (SYNGENE), and the
G. Tian et al. / Virology 341 (2005) 153–162160protein of the HA band (which has been confirmed by
Western blotting analysis using the H5HA DNA vaccine
immunized SPF chicken antisera in the preliminary
analysis) was quantified with the GenTools software using
the standard BSA protein. Then, the virus was inactivated
by adding 0.2% formalin (v/v) and kept at 37 -C for 24
h. Inactivation was confirmed by the absence of detect-
able infectivity after two blind passages of formalin-
treated allantoic fluid in embryonated eggs. One part of
the inactivated allantoic fluid was emulsified in 2 parts of
paraffin oil (Hangzhou Oil Refining Company, Hangzhou,
China) (volume/volume), which is currently used com-
mercially as adjuvant for veterinary vaccine production.
The HA protein content in the final vaccine preparation is
9.2 Ag/ml.
Immunogenicity and efficacy of a formalin-inactivated Re-1
virus vaccine in chickens, geese and ducks
Chickens
Two groups of thirty-two 3-week-old white Leghorn SPF
chickens were injected intramascular (i.m.) with 0.3 ml PBS
or formalin-inactivated vaccine preparations containing 2.8
Ag HA antigen. Sera were collected randomly from 8
chickens of each group on a weekly base for HI antibody
detection using the WHO standard method. Eight chickens
from each group were challenged with 107EID50 of the
homologous virus GSGD/96 intranasally at 2, 3 and 43
weeks, respectively, post-vaccination (p.v.). Oropharyngeal
and cloacal swabs of the chickens were collected on days 3,
5 and 7 post-challenge (p.c.) for virus titration, and chickens
were observed for disease signs and death for 2 weeks after
challenge.
Another experiment was conducted to evaluate the
protection against 2004 H5N1 isolates. Two groups of eight
3-week-old white leghorn chickens were vaccinated with
0.3 ml of the vaccine preparations and were challenged 3
weeks p.v. with 107EID50 of two H5N1 viruses, CKTJ/04
and DKSH/04, respectively. Oropharyngeal and cloacal
swabs of chickens were collected on days 3, 5 and 7 post-
challenge (p.c.) for virus isolation, and chickens were
observed for disease signs and death for 2 weeks after
challenge.
Geese
Laboratory studies. Groups of ten 3-week-old avian
influenza serological negative geese (local strain) were
injected intramuscularly (i. m.) with 0.5 ml PBS or Re-1
vaccine preparations (containing 4.6 Ag HA antigen), and
five geese from each group were challenged with 107.5
EID50 of DKSH/04, at 2 or 3 weeks after vaccination.
Oropharyngeal and cloacal swabs were collected on days
3, 5 and 7 post-challenge (p.c.) for virus isolation, and
geese were observed for disease signs and death for 2
weeks p.c.Field studies. We conducted the test on a small-scale
farm to learn the duration of the protective antibody and
efficacy induced by the inactivated vaccine in the geese.
The geese were serologically confirmed as avian influenza
negative by AGP test. Two hundred 2-week-old geese
were vaccinated with 0.5 ml of the vaccine preparations
containing 4.6 Ag of HA antigen, and the second and third
shots were applied with a high dosage of 1.5 ml of the
vaccine preparations containing 13.8 Ag of the HA protein
4 weeks and 17 weeks, respectively, after the first shot,
when the HI antibody titers reduced to 4log2. Sera were
collected randomly from 20 geese on a weekly base for HI
antibody detection. Every 2 weeks after vaccination,
oropharyngeal and cloacal swabs were collected randomly
from 20 of each type of birds for virus isolation. At the
end of observation periods, 10 geese were shipped to the
laboratory for the challenge study, as described above. The
same age avian influenza negative birds confirmed by
AGP test were used as control.
Ducks
Laboratory studies. Avian influenza serological negative
ducks were used. Groups of ten 3-week-old ducks (a local
outbred strain of sheldrake) were injected intramascular
(i.m.). with 0.5 ml of the vaccine preparations (containing
4.6 Ag HA antigen), another group of five ducks were
unvaccinated as a control. Ducks were challenged with 107.5
EID50 DKSH/04 3 weeks p.v. Oropharyngeal and cloacal
swabs were collected on days 3, 5, 7, 10, 20 and 30 days
post-challenge (p.c.) for virus titration. Ducks were
observed for disease signs and death for 30 days after
challenge. The duck experiments were repeated two more
times independently.
Field studies. Ducks in a small-scale farm were serolog-
ically confirmed as avian influenza negative by the AGP
test. Four hundred 4-week-old ducks were injected i.m.
with the vaccine preparations. Sera were collected ran-
domly from 20 ducks on a weekly base for HI antibody
detection. The second shot of 1 ml vaccine preparation
containing 9.2 Ag HA protein was applied at 14 weeks
after the first shot when the average HI antibody titer
declined to 4log2. Every 2 weeks after vaccination,
oropharyngeal and cloacal swabs were collected randomly
from 20 of birds for virus isolation. At the end of
observation periods, 10 ducks were shipped to the
laboratory for the challenge study. The same age avian
influenza negative birds were used as control.
Serologic tests and virus titration. Hemagglutination
inhibition assays were performed by following the WHO
standard. Each swab was washed in 1 ml cold PBS, and
virus titration was conducted in 10-day-old SPF embryo-
nated chickens’ eggs and calculated by the method of Reed
and Muench (1938).
G. Tian et al. / Virology 341 (2005) 153–162 161Laboratory facility. All experiments related to the HPAIV
were conducted in a P3 facility.Acknowledgments
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